

Product Name: DCAF16 / DDB1

Alternate Names: DCAF16 (DDB1- and CUL4-associated factor 16)

Product Code: TE3-024

FOR RESEARCH USE ONLY (RUO)

Verified Applications / Usage

DCAF16 / DDB1 is active in ternary complex formation assays using recombinant BRD4 and the degrader molecule KB02-JQ1.

Physical Characteristics

Species: Human

Predicted MW (kDa): DCAF16: 27 kDa
DDB1: 131 kDa

Source: Sf9 (*S. frugiperda*)

Purity: 90 %

Tags: DCAF16: N-His₈-TEV
DDB1: N-Twin-Strep-3C

Formulation: 40 mM HEPES, 100 mM NaCl, 10% Glycerol, 1 mM EDTA, 1 mM TCEP, pH 7.6


Shipping: The product is shipped with dry ice. Upon receipt, store it immediately at the temperature recommended below.

Stability/Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Aliquot and store ≤ -70°C.

Quality Assurance

Purity & SDS-PAGE

Protein ID: DDB1- and CUL4-associated factor 16,
DNA damage-binding protein 1



2 µg DCAF16 / DDB1 run on 4-12% SDS-PAGE gel under reducing conditions, then visualized with Colloidal Coomassie Blue Stain.

Activity Assay

Verified in Ternary Complex Assay.

Background

Description

DCAF16 is the substrate-receptor of the CUL4–RING E3 ligase CRL4-DCAF16. Recombinant human DCAF16 is co-purified as a stable heterodimer with its adaptor DDB1, retaining the binding site for reported DCAF16 electrophilic ligands. DCAF16 protein contains an N-terminal His₈-TEV tag, and DDB1 contains an N-terminal Twin-Strep-3C tag.

Accession Number: Q9NXF7

Entrez Gene ID: DCAF16

Accession Number: Q16531

Entrez Gene ID: DDB1

Protein Sequences

DCAF16:

MGHHHHHHHGHGSENLYFQSGMGPRNPSPDHLSESESEEEEEENISYLNESSGEEWDSSEEEDSMV
PNLSPLESLAWQVKCLLKYSTTWKPLNPNNSWLYHAKLLDPSTPVHILREIGLRLSHCSCVCPK
LEPIPEWPPPLASCGVPPFQKPLTSPSRLSRDHATLNGALQFATKQLSRTLRSRATPIPEYLKQI
PNSCVSGCCCGWLTKTVKETTTRTEPINTTYSYTDFOKAVNKLLTASL

DDB1:

MWSHPQFEKGGGSGGGSGGSAWSHPQFEKGSLEVLFGQPMSYNYVVTAQKPTAVNGCVTGHFT
SAEDLNLLIAKNTRLEIYVVTAEGLRPVKEVGMYGKIAVMELFRPKGESKDLLFILTAKYNAC
ILEYKQSGESIDIITRAHGNVQDRIGRPSETGIIGIIDPECRMIGLRLYDGLFKVIPLDRDNK
ELKAFNIRLEELHVIDVKFLYGCQAPTICFVYQDPQGRHVKTYEVSLREKEFNKGPWKQENVE
AEASMVIAVPEPFGGAIIGQESITYHNGDKYLAIAPPIIKQSTIVCHNRVDPNGSRYLLGDM
EGRLFMLLLEKEEQMDGTVTLKDLRVELLGETSIAECLTYLDNGVVFVGSRLGDSQLVKNVD
SNEQGSYVVAMETFTNLGPIVDMCVVDLERQGGQQLVTCGAFKEGSLRIIRNGIGIHEHASI
DLPGIKGLWPLRSDPNRETDLTLVLSFVGQTRVLMNLNGEEVEETELMGFVDDQQTFFCGNVAH
QQLIQITSASVRLVSQEPKALVSEWKEPQAKNISVASCNSSQVVAVGRALYYLQIHPQELRQ
ISHTEMEHEVAACLDITPLGDSNGLSPLCAIGLWTDISARIKLPKSFELLHKEMLGGEIIPRSI
LMTTFESSHYLLCALGDGALFYFGLNIETGLLSDRKKVTLGTQPTVLRFRSLSTTNVFCSD
RPTVIYSSNHKLVFSNVNLKEVNYMCPLNSDGYPDSLALANNSTLTIGTIDEIQKLHIRTVPL
YESPRKICYQEVSQCFGVLSSRIEVQDTSGGTALRPSASTQALSSSVSSSKLFSSTAPHET
SFGEEVEVHNLIIIDQHTFEVLHAHQFLQNEYALSLVSKLKGKDPNTYFIVGTAMVYPEEAEP
KQGRIVVFQYSDGKLQTVAEKEVKGAVYSMVEFNGKLLASINSTVRLYEWTTEKELRTECNHY
NNIMALYLKTKGDFILVGDLMRSVLLLAYKPMEGNFEEIARDFNPWNMSAVEILDNDNFLGAE
NAFNLFVCQKDSAATTDEERQHLQEVGLFHLGEFVNVFCHGSLVMQNLGETSTPTQGSVLFGT
VNGMIGLVTSLSESWYNLLLDMQNRLNKVIKSVGKIEHSFWRSFHTEKTEPATGFIDGLIE
SFLDISRPKMQEVVANLQYDDGSGMKREATADDLIKVVEELTRIH